PB0589 - Inflammatory markers and auto-Abs to type I IFNs in COVID-19 Convalescent Plasma

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

FC

Fabrice Cognasse

Senior Scientist, Director for Scientific Affairs
Etablissement Français du Sang Auvergne-Rhône-Alpes & INSERM 1059
Decines-Charpieu, Rhone-Alpes, France

Co-Author(s)

HH

Hind Hamzeh-Cognasse

Senior Scientist
SAINBIOSE Laboratory, INSERM, U1059, University of Lyon, Saint-Étienne
Saint-Etienne, Rhone-Alpes, France
BB

Brigitte Bonneaudeau

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
CP

Chloe Pierre

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
JH

Julie Huet

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
CA

Charles Antoine Arthaud

Technician
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
ME

Marie Ange Eyraud

Technician
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
AP

Amélie Prier

Technician
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Chapieu, Rhone-Alpes, France
OH

Olivier Hequet

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
AF

Anne-Marie Fillet

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
PC

Patricia Chavarin

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
DL

Dominique Legrand

Senior Scientist
Etablissement Français du Sang Auvergne-Rhône-Alpes
Decines-Charpieu, Rhone-Alpes, France
PR

Pascale Richard

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
FP

France Pirenne

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
JC

Jean Laurent Casanova

Senior Scientist
University of Paris, Imagine Institute, Paris, France
Paris, Ile-de-France, France
Sophie Susen, MD, PhD

Professor, MD, PhD
CRC-MHC, Lille University Hospital, Lille, France
Lille, Nord-Pas-de-Calais, France
PM

Pascal Morel

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France
KL

Karine Lacombe

Senior Scientist
Sorbonne Université, Inserm IPLESP, Infectious Diseases Department, Saint-Antoine Hospital, APHP
Paris, Rhone-Alpes, France
PB

Paul Bastard

Senior Scientist
University of Paris, Imagine Institute, Paris, France
Paris, Ile-de-France, France
PT

Pierre Tiberghien

Senior Scientist
Etablissement Français du Sang, La Plaine, St Denis, France
Saint-Denis, Ile-de-France, France

Background: COVID-19 convalescent plasma (CCP) contains neutralizing anti-SARS-CoV-2 antibodies that may be useful as COVID-19 passive immunotherapy in patients at risk of developing severe disease.

Aims: Such plasma from convalescent patients may also have additional immune-modulatory properties when transfused to COVID-19 patients.

Methods: CCP (n=766) were compared to control non-convalescent plasma (n= 166) for soluble inflammatory markers, ex-vivo inflammatory bioactivity on endothelial cells, neutralizing auto-Ab to type I IFNs, and reported adverse events in the recipients.

Results: CCP exhibited significantly higher IL-6 and TNF-alpha (0.531+/-0.04 vs 0.271+/- 0.04; p=0.0061 and 0.900+/-0.07 vs 0.283+/- 0.07 pg/mL; p< 0.0001), respectively) and lower IL-10 (0.731+/- 0.07 vs 1.22+/-0.19 pg/ mL, p=0.0034) levels than control plasma. Other inflammatory markers as well as ex-vivo bioactivity did not differ significantly between CCP and control plasma. Neutralizing auto-Abs against type I IFNs were detected in 14/766 (1,8 %) CCP. They were not associated with reported adverse events when transfused (n=14). Inflammatory markers and bioactivity in CCP with or without auto-Ab, or in CCP associated or not with adverse events in transfused patients, did not differ significantly. Overall, CCP exhibited moderately increased inflammatory markers compared to control plasma with no discernable differences in ex-vivo bioactivity. Auto-Ab to type I IFNs, detected in a small fraction of CCP, were not associated with reported adverse events or differences in inflammatory markers.

Conclusion(s): Further defining the clinical relevance of these findings will require further studies including careful clinical evaluation of patients treated with CCP.